+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endometriosis - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762888
  • Report
  • 130 pages
  • VPA Research
1 of 4


  • AbbVie
  • Bayer AG
  • Enteris BioPharma Inc
  • Forendo Pharma Ltd
  • Luye Pharma Group Ltd
  • Philogen SpA
  • MORE

Endometriosis pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Endometriosis R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Endometriosis report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Endometriosis as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Endometriosis with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Endometriosis pipeline Profiled in detail

Key players actively participating in Endometriosis pipeline are profiled along with their R&D progress in Endometriosis treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Endometriosis pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Endometriosis treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Endometriosis pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Endometriosis pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Endometriosis pipeline study
  • All recent news and developments related to Endometriosis drugs are provided
Note: Product cover images may vary from those shown
2 of 4


  • AbbVie
  • Bayer AG
  • Enteris BioPharma Inc
  • Forendo Pharma Ltd
  • Luye Pharma Group Ltd
  • Philogen SpA
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Endometriosis Disease Overview

3. Endometriosis R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Endometriosis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Endometriosis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Endometriosis companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Endometriosis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • AbbVie
  • Addex Therapeutics Ltd
  • Adynxx Inc
  • Auritec Pharmaceuticals Inc
  • Bayer AG
  • Chugai Pharmaceutical Co Ltd
  • ElexoPharm GmbH
  • EndoCeutics Inc
  • Enteris BioPharma Inc
  • Evestra Inc
  • Evotec AG
  • Forendo Pharma Ltd
  • Immune Biosolutions
  • Immunitor Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Luye Pharma Group Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Nippon Shinyaku Co Ltd
  • Ogeda SA
  • Philogen SpA
  • Predictive Therapeutics LLC
  • PregLem SA
  • Repros Therapeutics Inc
  • SK Chemicals Co Ltd
  • SYNG Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • Temple Therapeutics BV
  • ValiRx Plc
  • Viramal Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4762888